FCGR StripAssay
The FCGR StripAssay® is a specialized genetic testing kit designed for research purposes to identify variants FCGR2A-H131R and FCGR3A-F158V in the Fc gamma receptor gene. Utilizing a three-step process involving DNA isolation, PCR amplification, and hybridization, this assay aims to personalize cancer treatments. Studies indicate these FCGR gene variants can significantly influence the effectiveness of monoclonal antibody therapies in cancers like colorectal and breast cancer. The kit offers an all-in-one solution, including all necessary reagents and materials, enabling streamlined, reliable genotyping that may ultimately help optimize therapeutic strategies.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
- Genetic Profiling
- Quick Analysis
- All-Inclusive Kit
- Research-Grade Accuracy
- Therapy Optimization
The Impact and Utility of FCGR StripAssay® in Personalized Cancer Therapy
Introduction
Personalized medicine is becoming increasingly important in cancer therapy. One genetic feature that can significantly influence the efficacy of antibody-based therapies is the Fc gamma receptor (FCGR) gene. The FCGR StripAssay® identifies specific variants of this gene-namely FCGR2A-H131R and FCGR3A-F158V-providing a crucial tool for potentially optimizing cancer treatment strategies.
The Science Behind FCGR
Studies have shown that individuals carrying higher-affinity alleles, such as FCGR2A-131His (rs1801274) or FCGR3A-158Val (rs396991), show enhanced responses to monoclonal antibody therapies. In the context of colorectal cancer, 56% of patients with the FCGR3A-158 F/F genotype responded positively to treatments with cetuximab and bevacizumab. This number dropped significantly for patients with the heterozygous F/V and homozygous V/V genotypes, to 25% and 8%, respectively. Similarly, breast cancer patients with the genotypes FCGR2A-131 H/H and FCGR3A-158V/V showed favorable responses to trastuzumab therapy.
Methodology
The FCGR StripAssay® employs a three-step methodology that includes DNA isolation, PCR amplification using biotinylated primers, and hybridization of the amplification products to a test strip containing allele-specific oligonucleotide probes. The procedure is intended for research use only and focuses on detecting two polymorphic loci: FCGRIIA H131R and FCGRIIIA F158V.
Conclusion
The FCGR StripAssay® holds significant promise for the field of personalized cancer therapy. While additional research is needed to make FCGR genotyping a standard part of clinical decision-making, the potential benefits-particularly in optimizing antibody-based therapies-are undeniable. This assay could play a pivotal role in delivering more effective, personalized treatment plans for cancer patients.
- Lysis Solution (50 ml)
- GENXTRACT™ Resin (5 ml)
- Amplification Mix (500 µl, yellow cap)
- Taq Dilution Buffer (500 µl, transparent cap)
- DNAT (1.5 ml, blue cap)
- Typing Trays (3 units)
- Test Strips (20 units)
- Hybridization Buffer (25 ml, white cap)
- Wash Solution A (80 ml, white cap)
- Conjugate Solution (25 ml)
- Wash Solution B (80 ml)
- Color Developer (25 ml)
- Collector™ Sheet (1 unit)
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Instructions for Use
Frequently paired with this kit
Other assays and instruments lab teams add alongside the FCGR StripAssay.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
